



Received: 26-01-2026
Accepted: 06-03-2026

International Journal of Advanced Multidisciplinary Research and Studies

ISSN: 2583-049X

Comparative *in Vitro* Antibacterial Efficacy of *Peperomia Pellucida* Nanoemulsion, Gentamicin, and Silver Sulfadiazine Against Common Burn Wound Pathogens

¹ Casvin Jus, ² Arya Tjipta Prananda, ³ Eliza Nindita

¹ Department of Surgery, Faculty of Medicine, Universitas Sumatera Utara, Indonesia

^{2,3} Department of Surgery, Faculty of Medicine, Division of Plastic Surgery and Reconstructive Aesthetics, Universitas Sumatera Utara, Indonesia

DOI: <https://doi.org/10.62225/2583049X.2026.6.2.5985>

Corresponding Author: Casvin Jus

Abstract

Background: Burn wound infections remain a major cause of morbidity and mortality, predominantly caused by multidrug-resistant pathogens such as *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and methicillin-resistant *Staphylococcus aureus* (MRSA). Topical agents like silver sulfadiazine (SSD) and gentamicin are standard, but resistance and toxicity drive interest in natural alternatives. This study compared the *in vitro* antibacterial activity of *Peperomia pellucida* nanoemulsion (PPNE), gentamicin, and SSD against these pathogens.

Methods: An experimental post-test only control group design was employed. Clinical isolates or reference strains of *A. baumannii*, MRSA, and *P. aeruginosa* were cultured on Mueller-Hinton agar. Antibacterial activity was assessed using the Kirby-Bauer disk diffusion method with disks impregnated with PPNE (5%), gentamicin topical preparation, or SSD. Zone of inhibition (ZOI) diameters

were measured after 18–24 h incubation at 37°C (three replicates per group). Data were analyzed using Kruskal-Wallis test ($p < 0.05$ significant).

Results: PPNE produced the largest mean ZOI against *A. baumannii* (25.9 mm; strong activity), significantly outperforming gentamicin (17.0 mm) and SSD (11.3 mm) ($p = 0.005$). Against MRSA, ZOIs were comparable (PPNE 11.8 mm, gentamicin 11.3 mm, SSD 11.1 mm; all moderate; $p = 0.005$). For *P. aeruginosa*, PPNE (10.7 mm) and SSD (10.5 mm) showed moderate activity, superior to gentamicin (9.5 mm; weak-moderate; $p = 0.005$).

Conclusion: PPNE demonstrated superior or comparable *in vitro* antibacterial efficacy compared to conventional agents, particularly against *A. baumannii*. These findings support further *in vivo* and clinical evaluation of PPNE as a potential adjunct or alternative in burn wound infection management.

Keywords: Burn Wound Infection, *Peperomia Pellucida* Nanoemulsion, Silver Sulfadiazine, Gentamicin, Disk Diffusion, Antibacterial Activity

Introduction

Burn injuries compromise the skin barrier, predisposing patients to invasive infections that contribute to >75% of burn-related mortality globally. Common pathogens include *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and methicillin-resistant *Staphylococcus aureus* (MRSA), with increasing multidrug resistance complicating treatment. Topical antimicrobials such as 1% silver sulfadiazine (SSD) and gentamicin remain first-line agents for prophylaxis and treatment, yet concerns regarding delayed healing, resistance emergence, and systemic toxicity persist.

Peperomia pellucida (L.) Kunth, a Piperaceae herb with documented anti-inflammatory, antioxidant, and antimicrobial properties, has shown promise in wound healing models. Nanoemulsion formulations (PPNE) enhance bioavailability and delivery of bioactive compounds (e.g., flavonoids, phenolics). Recent preclinical data indicate PPNE accelerates burn wound closure via combined antimicrobial and anti-inflammatory effects. This *in vitro* study aimed to compare the antibacterial efficacy of PPNE, gentamicin, and SSD against predominant burn wound pathogens using the Kirby-Bauer disk diffusion method.

Methods

This experimental study employed a post-test only control group design and was conducted at the Department of Pharmaceutical Microbiology, Universitas Sumatera Utara, following ethical approval. Reference strains or clinical isolates of *Acinetobacter baumannii*, methicillin-resistant *Staphylococcus aureus* (MRSA), and *Pseudomonas aeruginosa* were cultured to 10^5 – 10^6 CFU/mL (McFarland 0.5 equivalent). Mueller-Hinton agar plates were inoculated using spread plate technique. Sterile 6-mm blank disks were impregnated with PPNE (5% concentration), gentamicin

topical preparation, or SSD and placed on plates (three disks per plate, three replicates per agent). Plates were incubated at 37°C for 18–24 h. Zones of inhibition (ZOI) were measured using digital calipers (mm). Activity was classified: <5 mm inactive; 5–10 mm weak; 10–20 mm moderate; >20 mm strong. Data were analyzed descriptively (mean $\pm$ SD) and inferentially using Kruskal-Wallis test with SPSS software ($p < 0.05$ significant).

Results

Table 1: Mean Zone of Inhibition Diameters (mm) Against *Acinetobacter baumannii*

Treatment	Replicate I	Replicate II	Replicate III	Mean $\pm$ SD	Interpretation	p-value*
Gentamicin	16.9	17.0	17.0	16.97 $\pm$ 0.06	Moderate	0.005
PPNE	26.8	25.5	25.4	25.90 $\pm$ 0.78	Strong	
Silver Sulfadiazine	11.0	11.7	11.3	11.33 $\pm$ 0.35	Moderate	

*Kruskal-Wallis test

Table 2: Mean Zone of Inhibition Diameters (mm) Against Methicillin-resistant *Staphylococcus aureus*

Treatment	Replicate I	Replicate II	Replicate III	Mean $\pm$ SD	Interpretation	p-value*
Gentamicin	11.2	11.3	11.3	11.27 $\pm$ 0.06	Moderate	0.005
PPNE	11.8	11.9	11.8	11.83 $\pm$ 0.06	Moderate	
Silver Sulfadiazine	11.4	10.8	11.1	11.10 $\pm$ 0.30	Moderate	

*Kruskal-Wallis test

Table 3: Mean Zone of Inhibition Diameters (mm) Against *Pseudomonas aeruginosa*

Treatment	Replicate I	Replicate II	Replicate III	Mean $\pm$ SD	Interpretation	p-value*
Gentamicin	9.8	9.0	9.7	9.50 $\pm$ 0.44	Weak-Moderate	0.005
PPNE	10.6	10.9	10.7	10.73 $\pm$ 0.15	Moderate	
Silver Sulfadiazine	10.2	10.7	10.5	10.47 $\pm$ 0.25	Moderate	

*Kruskal-Wallis test

PPNE exhibited significantly superior activity against *A. baumannii* (strong) and comparable or better activity against MRSA and *P. aeruginosa* (moderate) compared to gentamicin and SSD ($p < 0.05$ for all).

Discussion

This study demonstrates that PPNE possesses robust *in vitro* antibacterial activity against key burn wound pathogens, particularly outperforming gentamicin and SSD against *A. baumannii*. The strong ZOI (>20 mm) against *A. baumannii* aligns with emerging evidence of *Peperomia pellucida*'s broad-spectrum antimicrobial effects, likely mediated by flavonoids, phenolics, and nanoemulsion-enhanced diffusion.

Against MRSA, all agents produced moderate ZOIs with minimal differences, consistent with SSD's established activity against Gram-positive organisms and reports of *P. pellucida* efficacy against *S. aureus* strains. For *P. aeruginosa*, PPNE and SSD outperformed gentamicin, reflecting gentamicin's variable activity against *Pseudomonas* due to intrinsic resistance mechanisms (efflux pumps, biofilm).

These findings support prior reports of SSD's broad but sometimes limited efficacy in resistant strains and highlight the potential of natural nanoformulations to address resistance gaps. Limitations include the *in vitro* design (no eschar/biofilm simulation) and use of disk diffusion, which is formulation-dependent. PPNE's superior performance against *A. baumannii*—a notorious MDR pathogen in burns—suggests promise as an adjunct or alternative, warranting *in vivo* validation.

Conclusion

PPNE exhibited superior or comparable *in vitro* antibacterial efficacy to gentamicin and SSD against common burn wound pathogens, with particularly strong activity against *A. baumannii*. These results justify further preclinical and clinical studies to explore PPNE as a novel topical agent for burn wound infection control.

References

- Jeschke MG, Van Baar ME, Choudhry MA, *et al.* Burn injury. Nat Rev Dis Primers. 2020; 6(1):11.
- Seprilla G. Infection in burn wound patients: Microbiology, resistance patterns, and clinical impact. Jurnal MedScientiae. 2024; 3(2):45-54.
- Wardhana A, Basuki A, Dina A, *et al.* The epidemiology of burns in Indonesia's national referral burn center from 2013 to 2015. Burns Open. 2017; 1(2):67-73.
- Snelling CF, Ronald AR, Hatley J. Comparison of silver sulfadiazine and gentamicin for topical prophylaxis against burn wound sepsis. Can Med Assoc J. 1978; 119(5):466-470.
- Rosanova MT, Stamboulia D, Lede R. Which topical agent is more efficacious in the prevention of infections in burn patients? Systematic review. Arch Argent Pediatr. 2012; 110(4):298-303.
- Alves NS, Setzer WN, Da Silva JKR. The chemistry and biological activities of *Peperomia pellucida* (Piperaceae): A critical review. J Ethnopharmacol. 2019; 232:90-102.

7. Ahmad I, Hikmawan BD, Sulistiarini R, *et al.* Peperomia pellucida (L.) Kunth herbs: A comprehensive review. J Appl Pharm Sci. 2023; 13(1):1-9.
8. Prananda AT, Prayugo B, Dewi F, *et al.* Unveiling the functional food properties of Peperomia pellucida: Phytochemical profiling, antioxidative potential, and their nanoemulsion fraction in wound healing efficacy. J Agric Food Res. 2024; 16:101156.
9. CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests. 13th ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2018.
10. Yadav SK, Bhujel R, Hamal PK, *et al.* Burden of multidrug-resistant Acinetobacter baumannii infections. Infect Drug Resist. 2020; 13:3347-3362.
11. Okoh SO, Iweriebor BC, Okoh OO, *et al.* Bioactive constituents, radical scavenging, and antibacterial properties of the leaves and stem essential oils of Peperomia pellucida. Pharmacogn Mag. 2017; 13(Suppl 3):S636-S642.
12. Rahmawati D, Sari MP, Putri AN. Antibacterial activity of suruhan leaf extract (Peperomia pellucida) against Staphylococcus aureus. Indonesian J Pharm Sci. 2023; 21(1):33-39.
13. Ibrahim MA, *et al.* Phytochemical screening and antibacterial activity determination of Peperomia pellucida. Trends Biosci. 2020; 1(1):4-6.
14. Qin S, Xiao W, Zhou C, *et al.* Pseudomonas aeruginosa: Pathogenesis, virulence factors, antibiotic resistance mechanisms. Front Microbiol. 2022; 13:1039100.
15. Casabonne C, Dinh A, Salomon J. Antibacterial activity of silver sulfadiazine in wound and burn infections: An *in vitro* evaluation. Burns. 2022; 48(6):1391-1398.
16. Gunjan K, *et al.* A comparative study of the effect of different topical agents on burn wound infections. Indian J Plast Surg. 2012; 45(2):374-378.